Table 3.
Analyses of factors regarding OS
| Variables | n (%) | Number of death (%) | Estimate median OS (range) | 3-year survival rate (%) | 5-year survival rate (%) | Log-rank test χ2 value | P-valuea |
|---|---|---|---|---|---|---|---|
| Age (years) | 0.058 | ||||||
| <60 | 99 (53.8) | 52 (52.5) | 53.1 (25.5–80.6) | 55.58 | 45.10 | 3.584 | |
| ≥60 | 85 (46.2) | 56 (65.9) | 31.0 (21.9–40.1) | 44.56 | 28.58 | ||
| Gender | 0.146 | ||||||
| Male | 132 (71.7) | 74 (56.1) | 40.5 (29.7–51.4) | 53.57 | 40.0 | 2.114 | |
| Female | 52 (28.3) | 34 (65.4) | 27.4 (19.9–35.0) | 42.27 | 30.25 | ||
| Tumor size (cm2)b | 0.003 | ||||||
| <16 | 76 (41.3) | 35 (46.1) | 70.1 (42.8–97.4) | 65.06 | 53.77 | 8.773 | |
| ≥16 | 88 (47.8) | 57 (64.8) | 33.8 (17.9–49.7) | 45.77 | 29.20 | ||
| Histological grade | 0.001 | ||||||
| 1/2 | 46 (25.0) | 32 (69.6) | 42.3 (30.6–53.9) | 34.70 | 19.28 | 10.301 | |
| 3/4 | 138 (75.0) | 76 (55.0) | 19.9 (8.1–31.8) | 55.73 | 43.60 | ||
| Lymph nodes metastasis | 0.015 | ||||||
| Yes | 131 (71.2) | 83 (63.4) | 31.03 (19.9–42.2) | 46.56 | 30.53 | 5.895 | |
| No | 53 (28.8) | 25 (47.2) | 76.3 (47.6–104.9) | 60.15 | 52.93 | ||
| Serosal invasion (T stage) | <0.001 | ||||||
| T1–2 | 27 (14.7) | 7 (25.9) | 38.7 (30.3–47.0) | 79.72 | 74.89 | 14.742 | |
| T3–4 | 157 (85.3) | 101 (64.3) | 30.1 (20.2–40.1) | 45.43 | 30.78 | ||
| TNM | 0.002 | ||||||
| Early (stage I, II) | 58 (31.5) | 26 (44.8) | 76.3 (50.1–102.5) | 63.0 | 54.00 | 9.823 | |
| Advanced (stage III, IV) | 126 (68.5) | 82 (65.1) | 30.1 (15.7–44.5) | 44.72 | 29.20 | ||
| Recurrence | <0.001 | ||||||
| No | 124 (67.4) | 52 (41.9) | 94.8 (43.9–145.7) | 64.86 | 55.44 | 46.442 | |
| Yes | 60 (32.6) | 56 (93.3) | 19.3 (16.6–22.0) | 23.0 | 5.90 | ||
| Infiltrating macrophages density | 0.349 | ||||||
| Low | 125 (67.9) | 70 (56.0) | 39.87 (25.2–54.5) | 52.31 | 39.35 | 0.878 | |
| High | 59 (32.1) | 38 (64.4) | 34.1 (20.3–47.9) | 46.58 | 29.74 | ||
| MVD | 0.048 | ||||||
| Low | 42 (22.8) | 21 (50.0) | 70.0 (53.0–87.0) | 67.94 | 49.66 | 3.922 | |
| High | 142 (77.2) | 87 (61.3) | 31.0 (21.4–40.6) | 45.25 | 33.84 | ||
| Neovessels’ maturity | <0.001 | ||||||
| Low | 87 (47.3) | 66 (75.9) | 19.7 (12.5–26.9) | 26.72 | 16.09 | 33.442 | |
| High | 97 (52.7) | 42 (22.8) | 70.1 (43.2–97.0) | 70.44 | 54.94 | ||
| Type IV collagen | <0.001 | ||||||
| Negative | 92 (50.0) | 64 (69.6) | 25.8 (19.0–32.7) | 39.17 | 22.95 | 15.152 | |
| Positive | 92 (50.0) | 44 (47.8) | 70.1 (44.7–95.5) | 61.53 | 51.02 | ||
| LOX | <0.0001 | ||||||
| Negative | 92 (50.0) | 36 (39.1) | 94.8 (35.9–153.7) | 71.42 | 57.56 | 33.312 | |
| Positive | 92 (50.0) | 72 (78.3) | 20.2 (14.2–26.2) | 30.64 | 17.38 | ||
| MMP-9 | <0.0001 | ||||||
| Negative | 92 (50.0) | 34 (37.0) | 38.7 (30.4–47.0) | 73.39 | 57.00 | 52.341 | |
| Positive | 92 (50.0) | 74 (80.4) | 16.8 (12.3–21.3) | 27.19 | 17.18 |
Notes:
a
Bold indicates values with a significant difference (P<0.05).
b
Analysis was performed based on 164 patients with complete data of tumor size.
Abbreviations: OS, overall survival; MVD, microvessel density; LOX, lysyl oxidase; MMP-9, matrix metalloproteinase 9.